Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
The Fly

Verona Pharma price target raised to $42 from $36 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 report. The firm says Ohtuvayre beat its forecasts. Initial receptivity among key prescribing physicians appears highly favorable and indicative of broad market acceptance, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App